[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"controlled-human-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:controlled-human-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100493512","phase-1-controlled-human-infection-study-of-orally-administered-trichuris-trichiura-eggs-in-nave-adults-100493512",false,"NCT05706116","Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults","A Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults","Inclusion Criteria:\n\n1. Males or females between 18 and 45 years, inclusive.\n2. Good general health as determined by means of the screening procedures.\n3. Available for the duration of the trial (approximately 7.5 months).\n4. Willingness to participate in the study as evidenced by signing the informed consent document.\n5. Ability to sign and understand the informed consent document.\n\nExclusion Criteria:\n\n1. Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female).\n2. Participant unwilling to use reliable contraception methods while participating in the study (if female of reproductive potential who is engaging in sexual activity that could lead to pregnancy); being of reproductive potential is defined as not being surgically sterile, abstinent from intercourse with a male partner, in a monogamous relationship with a vasectomized partner, at least 2 years post-menopausal, or determined otherwise by medical evaluation to be sterile.\n3. Currently lactating and breast-feeding (if female).\n4. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and\u002For laboratory studies.\n5. Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition that would make compliance with study visits\u002Fprocedures difficult (e.g., subject with psychoses or history of suicide attempt or gesture in the 3 years before study entry, ongoing risk for suicide).\n6. Known or suspected immunodeficiency or immunosuppression as a result of an underlying illness or treatment.\n7. Laboratory evidence of liver disease (alanine aminotransferase \\[ALT\\] greater than 1.25-times the upper reference limit).\n8. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit).\n9. Laboratory evidence of hematologic disease (hemoglobin \\\u003C11.1 g\u002Fdl \\[females\\] or \\\u003C12.5 g\u002Fdl \\[males\\]; absolute leukocyte count \\\u003C3.4 or \\>11.0 x 103\u002Fmm3; absolute eosinophil count \\>0.6 x 103\u002Fmm3 or platelet count \\\u003C125 x 103\u002Fmm3).\n10. Positive fecal occult blood test.\n11. Infection with a pathogenic intestinal helminth as determined by stool examination for ova and parasites.\n12. History of iron deficiency anemia or laboratory evidence of iron deficiency (serum ferritin concentration below the lower reference limit).\n13. Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the participant unable to comply with the protocol.\n14. Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 24 months.\n15. Positive ELISA for hepatitis B surface antigen (HBsAg).\n16. Positive confirmatory test for HIV infection.\n17. Positive confirmatory test for hepatitis C virus (HCV) infection.\n18. Using or intends to continue using oral or parenteral corticosteroids, high-dose inhaled corticosteroids (\\>800 μg\u002Fday of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days of the volunteer's expected enrollment in this study or planned use during the study.\n19. Known allergy to albendazole.\n20. History of previous infection with T. trichiura or continuous residence for more than 6 months in a T. trichiura-endemic area.\n21. Inability to speak English.\n22. Current\u002Fplanned simultaneous participation in another study of an investigational agent or device for the duration of their study participation.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","A Controlled Human Infection Model (CHIM) is being developed to provide early proof-of-concept that experimental infection with the intestinal nematode, Trichuris trichiura, is feasible and safe. The proposed model consists of enrolling consenting, healthy, trichuriasis-naïve adults and challenging them with the investigational product, Trichuris trichiura Egg Inoculum, to assess their ability to result in detectable infection. The proposed study will be a feasibility study that will consist of administering different doses of the Trichuris trichiura Egg Inoculum to healthy adult volunteers to determine the optimal dose (i.e., number of T. trichiura eggs) that is safe, well-tolerated and results in consistent infection.",[28,29,30],"Whipworm","Trichuriasis","Controlled Human Infection","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2025-09-10",{"date":39,"type":22},"2028-04-30",{"name":41,"class":42},"George Washington University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100570061","clostridioides-difficile-controlled-human-infection-model-100570061","NCT06702345","Clostridioides Difficile Controlled Human Infection Model","Establishing a Clostridioides Difficile Controlled Human Infection Model","CloDiCHI","Inclusion Criteria:\n\n1. Subject is aged ≥18 and ≤45 years and in good health;\n2. Body mass index (BMI) ≥18.0 and \\\u003C30.0 kg\u002Fm2;\n3. Subject has adequate understanding of the procedures of the study and is able and willing to abide strictly thereby;\n4. Subject is able to communicate well with the investigator, is willing to follow hygienic measures and instructions;\n5. For women of childbearing potential: subject agrees to use adequate contra-ception (see Appendix D for the different adequate contraception methods for this study) and not to breastfeed for the duration of the study;\n6. Subject has signed informed consent.\n\nExclusion Criteria:\n\n1. Any physical or psychiatric illness or conditions that could threaten or com-promise the health of the subject during the study, influence their ability to par-ticipate in the trial or interfere with the interpretation of the study results, as de-termined by the trial physician;\n2. Use of systemic (IV or oral) antibiotics within three months prior to screening; other microbiota influencing medication (that could influence the trial, based on the Investigator's opinion) within 1 month prior to screening visit. Prior use of topical antibiotics is permitted if there is no clinically relevant systemic ex-pected following assessment of the trial physician and are expected to be dis-continued during the start of the first study activity.\n3. Has had a recent hospitalization (e.g. 3 months prior to screening) and\u002For has someone in immediate social circle who is frequently hospitalized (≥3 times in a 12-month period) or frequently exposed to hospital settings (≥ one time a month, e.g. dialysis units);\n4. Regular use (defined by more than once weekly) of proton-pump inhibitors or H2-blockers during one month prior to screening;\n5. Chronic use of immunosuppressive drugs, e.g. systemic corticosteroids or other immune modifying drugs (with exception of oral anti-histamines and top-ical\u002Finhaled corticosteroids);\n6. Positive HIV, Hepatitis B or C screening tests;\n7. Known immunodeficiency disorders;\n8. The use of strong P-glycoprotein-inhibitors (like ciclosporin, ketoconazole, erythromycin, clarithromycin, verapamil and amiodaron) during the trial;\n9. Known allergy to vancomycin, clindamycin, fidaxomicin (and macrolides), or metronidazole;\n10. Any known significant allergy against the excipients of C. difficile inoculum or inability to swallow capsules;\n11. Known gastro-intestinal disease including but not limited to inflammatory bow-el diseases (Crohn's disease, Colitis ulcerosa), a history of bowel resection or any other gastro-intestinal surgery which has significantly changed the ana-tomical structure or physiological function of the gastro-intestinal tract, bile ac-id secretion abnormalities, constipation defined by bowel movements less than every second day or chronic use of laxatives;\n12. Positive fecal culture or PCR with toxigenic or non-toxigenic Clostridioides spp. or SSYC (Salmonella spp., Shigella spp., Yersinia spp. or Campylobac-ter spp.) at screening, or recent (\\\u003C14 days) history of diarrhoea (i.e. as ≥3 loose stools (Bristol stool scale 6-7) in 24 hours);\n13. Any condition that would put household members or close contacts at a great-er risk for transmission e.g. no access or use of flush toilet;\n14. Individuals living, working or having close contact with people who belong to vulnerable populations such as hospitalized patients, pregnant women, im-mune compromised individuals, children younger than 2 years, residents of nursing homes, elderly older than 70 years of age, or any person with a medi-cal condition at risk of developing severe CDI.\n15. Individuals working in food preparation;\n16. Individuals having close contact with healthcare personal\u002Findividuals working in food preparation;\n17. For women of childbearing potential; a positive serological pregnancy test at screening or lactating at screening\u002F during the trial;\n18. History of drug or alcohol abuse interfering with normal social functioning in the period of one year prior to study onset, positive urine toxicology test for il-licit drug use at screening;\n19. Receipt of another investigational agent within 90 days prior or 60 days after C. difficile ingestion;\n20. Any condition or situation that could influence the independent consent of par-ticipant (e.g. being a direct colleague or family member of study personnel).",{"count":52,"type":22},60,[54],"NA","This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea. It is also examined which dosing regimen (with or without antibiotic pretreatment) is required to induce mild symptoms (like diarrhoea) in the majority of study subjects and which microbiota and immunological factors influence this.\n\nTo investigate this, healthy adult study subjects will be asked to ingest capsules (pills) containing the Clostridioides bacterium.",[57,58,30],"C. Difficile","C. Difficile Infection","NOT_YET_RECRUITING","2024-11-20",{"date":62,"type":35},"2024-11-22",{"date":64,"type":22},"2025-03-01",{"date":66,"type":22},"2026-12-31",{"name":68,"class":42},"Leiden University Medical Center",1]